• 1. Emergency Section 2 of Public Health Clinical Center of Chengdu, Chengdu, 610061, P.R.China;
  • 2. Department of Tuberculosis of Public Health Clinical Center of Chengdu, Chengdu, 610061, P.R.China;
  • 3. Respiratory Department of West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;
  • 4. Department of Cardiology of West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;
YU He, Email: 27902682@qq.com
Export PDF Favorites Scan Get Citation

At present, there has been no report in China that novel coronavirus specific immune globulin has been used to treat coronavirus disease 2019 (COVID-19). Recently, we had successfully treated one COVID-19 patient with intravenous injection of human immunoglobulin (COVID-19-IVIG). The female patient, aged 57 years, had clinical diagnosis: (1) COVID-19, common type; (2) postoperative colon cancer; (3) leukopenia; (4) low cellular immunity. 75 mL COVID-19 human immunoglobulin (Sinoptic Wuhan Blood Products Co., Ltd.) was intravenously injected twice. The patient was hospitalized for 49 days and had a good prognosis.

Citation: MAO Yi, YU He, LIANG Zongan, WEI Jiafu, WU Guihui, LUO Haixia. Treatment of COVID-19 with COVID-19-human immunoglobulin: A case report. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2021, 28(11): 1388-1392. doi: 10.7507/1007-4848.202101061 Copy

  • Previous Article

    Research progress of endoscopic vacuum-assisted closure therapy for esophageal fistulas
  • Next Article

    重视腹主动脉瘤的规范化治疗